Purpose of Review Although significant progress has been made in cancer research, there exist unmet needs in patient care as reflected by the BCancer Moonshot^goals. This review appreciates the potential utility of quantitative pharmacology in cancer precision medicine. Recent Findings Precision oncology has received federal funding largely due to BThe Precision Medicine Initiative.^Precision medicine takes into account the inter-individual variability and allows for tailoring the right medication or the right dose of drug to the best subpopulation of patients who will likely respond to the intervention, thus enhancing therapeutic success and reducing Bfinancial toxicity^to patients, families, and caregivers. The National Cancer Institute (NCI) committed US$70 million from its fiscal year 2016 budget to advance precision oncology research. Through the BCritical Path Initiative,^pharmacometrics has gained an important role in drug development; however, it is yet to find widespread clinical applicability. Summary Stakeholders including clinicians and pharmacometricians need to work in concert to ensure that benefits of model-based approaches are harnessed to personalize cancer care to the individual needs of the patient via better dosing strategies, companion diagnostics, and predictive biomarkers. In medical oncology, where immediate patient care is the clinician's primary concern, pharmacometric approaches can be tailored to build models that rely on patient data already digitally available in the electronic health record (EHR) to facilitate quick collaboration and avoid additional funding needs. Taken together, we offer a roadmap for the future of precision oncology which is fraught with both challenges and opportunities for pharmacometricians and clinicians alike.
Introduction
Precision medicine as defined by the US Food and Drug Administration (FDA) is an Binnovative approach to tailoring disease prevention and treatment that takes into account differences in people's genes, environments, and lifestyles [ 1] and has received tremendous encouragement, federal funding, and public recognition from the Precision Medicine Initiative [2] announced by President Obama in the 2015 State of the Union Address in the USA. Indeed, precision medicine takes into account the individual variability between patients; hence, it allows for tailoring the right medication or the right dose of drug to the best subpopulation of patients who will likely respond to the intervention, thus enhancing therapeutic success and reducing Bfinancial toxicity^to patients, families, and caregivers. The historical term Bpersonalized medicine,â lthough often used interchangeably with Bprecision medicine,^refers more to an individualized treatment that caters more exclusively to the needs of a single patient, and is largely being replaced by the term Bprecision medicine^in most current day scenarios. With advances in basic research, molecular biology, genomics, and indeed bioinformatics, it is This article is part of the Topical Collection on Precision Medicine and Pharmacogenomics more possible today to apply precision medicine to clinical scenarios with the availability of large-scale biologic databases (human genome sequence), patient characterization methods (proteomics, genomics, metabolomics), and computational (big data) analysis tools at our disposal [3] . Out of a total of US$215 million from the Precision Medicine Initiative invested in the National Institute of Health (NIH)'s fiscal year 2016 budget, the National Cancer Institute (NCI) is using US$70 million to advance the field of precision oncology (or cancer precision medicine) and has launched several precision medicine clinical trials such as Lung-MAP, ALCHEMIST, NCI-MPACT, NCI-MATCH, and NCI-COG Pediatric MATCH trials [4] .
Pharmacometrics is a broad umbrella term that encompasses and describes all of drug, disease, and clinical trial i n f o r m a t i o n i n a q u a n t i t a t i v e m a n n e r. C l i n i c a l pharmacometrics refers to pharmacometrics when applied specifically to clinical pharmacology for therapeutic use in patients. Pharmacometric approaches have found applicability in the drug development scenario in pharmaceutical industry; however, their application to clinical situations in oncology is only truly beginning and is limited by the need for a collaborative framework between clinicians and pharmacometricians in a hospital oncology care setting where immediate patient care is the prime concern. Translational pharmacometrics can include the entire gamut of pharmacometric approaches from bench to bedside. For example, Cook and Bies [5] have reviewed key concepts in disease progression modeling elsewhere. However, the real value of clinical pharmacometrics is in aiding the clinician in tailoring the treatment to suit the appropriate subpopulation of patients, or in deciding the right dose for therapeutic efficacy, or in identifying a companion diagnostic or predictive biomarkers for faster clinical intervention in the specific patient population to cite a few examples. In this review, we draw attention to some of the recent advances in clinical pharmacometrics in precision oncology care and highlight the immense potential and benefits of such approaches going forward to enable better therapeutic success for the cancer patient and eventually lower the rising costs of cancer care through tailor-made precision medicine for appropriate subpopulations.
Clinical Pharmacometrics for Cancer Precision Medicine
Although significant progress has been made in cancer research, there still exist unmet needs in patient care as reflected by the Cancer Moonshot [6] initiative. Through the Critical Path Initiative, the US FDA has been promoting quantitative modeling in drug development since 2004 [7, 8] . Thus, pharmacometrics has gained a critical role in drug development settings (model-based drug development, MBDD) especially in big pharma industry; however, the use of pharmacometric approaches in the clinical setting (modelbased patient care [9] ) is currently nascent. Stakeholders such as clinicians and pharmacometricians need to work in concert to ensure that the benefits of model-based epistemology are harnessed to personalize cancer care to the individual needs of the patient via better dosing strategies, companion diagnostics, predictive biomarkers, etc. Recently, it has been advocated that routinely collected medical record data in hospitals may be used to generate population models in oncology clinical care settings by encouraging collaborations between clinicians and pharmacometricians without the financial burden of a formal study [10] . We review some of the examples in the literature under various variables that impact upon cancer precision medicine for the benefit of the reader as follows.
Pharmacokinetic-Guided Dosing
Patel et al. [11] administered the mFOLFOX6 regimen with 5-fluorouracil (5-FU) at a dose of 2400 mg/m 2 over 46 h every 2 weeks to 70 colorectal cancer patients. Interestingly, the continuous infusion dose for 5-FU was adjusted for cycles subsequent to the first cycle using a pharmacokinetic (PK)-guided algorithm in order to attain a pre-determined target area under the AUC (area under the plasma concentration time curve). The novel PK-guided algorithm achieved the target AUC within four cycles of dosing and translated into less GI toxicity and fewer underdosed patients thus enabling personalized cancer therapy for these colorectal cancer patients. In another study on 84 colorectal cancer patients (stages 2-4) administered with mFOLFOX6 or mFOLFIRI regimens, Kline et al. [12] administered 46 patients with 5-FU doses based on body surface area and 38 patients with 5-FU doses that were adjusted based on PK monitoring. It was observed that personalized dosing by 5-FU PK monitoring improved disease-free survival and reduced adverse drug reactions (ADR) in stage 2-3 patients of colorectal cancer. Notably, Pauley et al. [13] used between-course individualized dose adjustments of high-dose methotrexate in 485 patients with acute lymphoblastic leukemia (ALL). The doses were adjusted based on clearance values from previous course of highdose methotrexate for each individual and resulted in fewer extreme steady-state plasma concentration (Cpss) values and faster excretion as compared to conventional dosing resulting in fewer grades 3-4 toxicities.
Inter-individual Variation in Drug-Metabolizing Enzymes
Takashina et al. [14] evaluated the influence of gene polymorphisms on fentanyl PK and central ADR in 60 Japanese cancer patients undergoing conversion to a fentanyl transdermal reservoir system. In this study, the CYP3A5*3/ *3 allele group showed higher plasma concentrations as well as higher incidence of central ADR than the *1/*1 and the *1/*3 groups. Further, fewer patients carrying the ABCB1 1236TT allele required rescue medication as opposed to the 1236C allele. Thus, these gene polymorphisms clearly affected the PK of fentanyl and may be used as a personalized diagnostic to predict clinical response in patients being converted to the transdermal fentanyl delivery system. Interestingly, Cai et al. [15] studied the association between IVS14+1 G>A genotype of the dihydropyrimidine dehydrogenase (DPD) with 5-FU plasma concentrations and ADR in 80 metastatic colorectal cancer patients. This study showed that the 5-FU dose for patients with heterozygous DPD IVS14+1 mutation should be reduced to mitigate ADR, while homozygous patients should avoid 5-FU administration.
Gender and Geriatric
Pfreundschuh et al. [16] investigated higher rituximab doses for elderly male patients with diffuse large B cell lymphoma (DLBCL) as the male sex in these patients are associated with unfavorable PK and prognosis. Two hundred sixty-eight patients (120 female, 148 male) in the age group of 61-80 years received 6 cycles of CHOP and 8 cycles rituximab (males 500 mg/m 2 , females 375 mg/m 2 ). At this dose level, the exposure in males was slightly better than that in females. In a planned subgroup analysis for elderly males, the 500 mg/m 2 dose was not more toxic than the 375 mg/m 2 dose and improved progression-free survival (PFS). Indeed, the sex-specific PK study enabled safe and personalized administration of higher rituximab dose in elderly males and negated the adverse prognosis of male sex devoid of any increase in toxicity.
Pediatric
Zhou et al. [17] reported the first population PK study of vancomycin in the pediatric age group with malignant hematological disease so as to define the appropriate dosing regimen for these children. Seventy children in the age group of 0.3 to 17.7 years were administered 40 to 60 mg/kg/day of vancomycin and a patient-tailored dosing regimen was optimized. Traditional pediatric dose (mg/kg basis) simulations as well as patient-tailored dose simulations were performed. It was shown that the patient-tailored approach decreased variability in vancomycin AUC and steady-state trough concentrations (Css/min) as opposed to the milligrams/kilogrambasis dose and that a greater number of patients (60%) in the patient-tailored arm reached the target Css/min than with the milligrams/kilogram-basis dose (49%).
Predictive Biomarkers
Buil-Bruna et al. [18] used mechanism-based PK/PD (pharmacokinetic/pharmacodynamic) modeling to identify predictive biomarkers for early prediction of disease progression in small-cell lung cancer (SCLC) thus enabling personalized medicine with efficient therapeutic intervention for at-risk patients. Twenty-two treatment-naïve SCLC patients were administered first-line chemotherapy (etoposide plus either carboplatin or cisplatin). Biomarker samples for serum lactate dehydrogenase (LDH) and neuron-specific enolase (NSE) were obtained during the treatment period and a biomarker model was developed and validated externally. An encouraging result of this study was that biomarker data that was gathered only during the treatment period was sufficient to reliably predict 75% of follow-up tumor assessment results.
A semi-mechanistic model including K/PD compartments and a cell lifespan model has been used to describe the kinetics of circulating tumor cell (CTC) count and prostate-specific antigen (PSA) concentration to predict treatment efficacy or for therapeutic adjustment in metastatic castration-resistant prostate cancer [19] . CTC is a surrogate marker that may potentially replace the largely popular PSA. The model used data from 223 patients treated by chemotherapy and/or hormonotherapy and quantified the dynamic relationships between the longitudinal kinetics of both these markers during treatment.
Tumor Dimensions and FDG-PET Response
Schindler et al. [20] performed pharmacometric modeling of diameter, density, and volume of liver metastases to guide early beneficial interventions in imatinib-treated patients with gastrointestinal stromal tumors (GIST). In another study [21] , PK/PD modeling was used on individual lesion fludeoxyglucose (FDG)-PET response to serve as a predictor for overall survival in patients with sunitinibtreated GIST.
Systems Pharmacology
To assess the potential for optimal preloading with anti-CD20 antibody radioimmunotherapy, Kletting et al. [22] developed a PBPK model to describe the biodistribution of this antibody. Simulations were conducted using MATLAB Simulink for varying tumor permeabilities, spleen sizes, and tumor burdens, and the optimal amount of unlabeled antibody was identified. It was found that individual parameters, most notably the tumor uptake index, greatly influenced the optimal preload. The study concluded that personalized dosing for anti-CD20 antibody radioimmunotherapy is imperative to account for interpatient variability and, in general, a reduction of antibody is advocated. Interestingly, Gallo and Birtwistle [23] have described enhanced PD (ePD) models based on systems pharmacology and incorporating genetic data that would be useful along with PK/ePD models for customizing precision medicine in cancer care.
In addition, Majid et al. [24••] constructed a population PK model of eribulin combining data from seven phase 1 studies, one phase 2 study, and one phase 3 study, as well as a PK/PD model of efficacy and tumor response, to describe eribulin exposure-response relationships and better inform clinicians treating patients with metastatic breast cancer. In this study, inter-individual variability was found to be 52% for both clearance and exposure. Further, liver function markers such as albumin, bilirubin, and alkaline phosphatase contributed 7.3% of inter-individual variability in clearance of eribulin thus significantly impacting eribulin PK.
Exposure-response analyses were performed on guadecitabine, a hypomethylating agent, along with modeling and simulation incorporating DNA demethylation and absolute neutrophil count (ANC) from 79 and 369 patients in two phase 1/2 studies to predict the optimal dosing regimen for phase 3 in myeloid malignancies [25] . Herein, an indirect response model described the long interspersed nucleotide element (LINE-1) methylation time course whereas a K/PD model linked the dosing rate with decrease in ANC.
Metronomic Chemotherapy
A metronomic regimen of cancer chemotherapy is an alternative dosing schedule which involves repeated and regular administration of low-dose cancer chemotherapeutics [26] . Metronomic chemotherapy has several advantages including lower treatment costs, lower toxicity, and commendable efficacy that is superior to that of maximum-tolerated-dose (MTD) therapy [27] . Indeed, metronomic regimens tend to be highly empirical in nature with difficulties in standardizing an optimal dose or treatment schedule [28] , and, hence, there is an unmet need to generate PK data of critical oncology drugs administered in metronomic regimens. Thus, theoretical model-based strategies [26] are imperative to refine dose and treatment schedules for the success of precision medicine in oncology. For example, Ciccolini et al. [29] reported a PK/PD model to identify the most effective administration schedule for metronomic chemotherapy with gemcitabine.
Hematopoietic Cell Transplant
McCune et al. [30] developed a population PK model for initial and Bayesian dose personalization after intravenous administration of busulfan to 1610 hematopoietic cell transplant recipients. In this study, the target Css of 770 ng/mL was achieved over a wide age spectrum from infants to adults, with a greater proportion of initial doses achieving the therapeutic window with this model (72%) as opposed to dosing recommended by the FDA (57%) or the European Medicines Agency (EMA, 70%). To minimize the ADR such as oral mucositis, GI, and liver toxicity with intravenous melphalan in hematopoietic stem cell transplantation, Mizuno et al. [31] developed a population PK model to individualize exposure using 15 adult patients administered 140 or 200 mg/m 2 of melphalan by intravenous infusion. An optimal sampling strategy was developed for modelbased precision dosing of melphalan in these patients. Further, Sanghavi et al. [32] developed a PK model to personalize fludarabine dosing in patients undergoing hematopoietic stem cell transplant with reduced intensity conditioning (RIC). The PK model from 87 adults predicted population clearance of F-ara-A, the active component of fludarabine, accounting for kidney function and body weight. This personalized dosing model would also be useful in obese and impaired kidney function patients.
Pharmacogenomics of Monoclonal Antibodies
We have previously described [33••] in detail key pharmacometric variables in the anticancer efficacy of anti-PD-1 immune checkpoint inhibitor nivolumab including target engagement, metabolism, systems pharmacology, and clearance. We have also summarized [34] ongoing and completed phase 1, 2, and 3 clinical trials investigating the safety and anticancer efficacy of anti-platelet-derived growth factor receptor (PDGFR) alpha mAb olaratumab which recently received accelerated approval, orphan drug status, fast track, and breakthrough therapy designation from the US FDA for metastatic soft tissue sarcoma. Since PD-L1, a ligand for PD-1, is a weak biomarker for nivolumab therapy in clinical practice [33••] , model predictions for the best responders in a stratified patient population when coupled with immunopharmacogenomic studies would enable greater therapeutic success through tailoring the precise treatment to the right patients and also serve to lower the Bfinancial toxicity^to patients and families. Similarly, since soft tissue sarcomas are heterogeneous with 50 different histologic subtypes, pharmacometric modelbased approaches can help understand and investigate (i) whether subsets of patients with higher PDGFR alpha expression might have potentially longer progression-free survival or overall survival benefit on treatment with olaratumab, or (ii) whether any subset of PDGFR alphaexpressing patients may not respond to olaratumab but may benefit from combination therapy with olaratumab and doxorubicin, the current standard of care [34] .
Chronic Kidney Disease
Khosravan et al. [35] conducted a phase 1, single-dose study to study the PK of sunitinib at a dose of 50 mg and found that exposure of receptor tyrosine kinase inhibitor sunitinib was decreased in subjects that had end-stage renal disease potentially leading to lower efficacy. Janus and Launay-Vacher [36] have excellently reviewed elsewhere why clinicians need to be aware of the need to individualize treatment in hemodialysis patients who are increasingly being prescribed anticancer drugs.
Population Pharmacogenomics and Pharmacometrics
In discovery research in the pharmaceutical industry, population pharmacogenetics could be employed to optimize clinical trial design by appropriate stratification of patient populations, in identifying at-risk patients for serious adverse events Table 1 The road to the future: challenges and opportunities in precision oncology
Challenges in precision oncology
Opportunities in precision oncology
Lack of validated disease signatures to assist the medical oncologist
Pharmacometric models can help identify a panel of tissue and blood biomarkers or companion diagnostics as onco-signatures that can be validated rapidly in the laboratory.
Low predictive power of oncobiomarkers that dampens the enthusiasm of the clinician Pharmacometric approaches can help assess a large pool of oncobiomarkers to identify those with higher predictive power based on efficient modeling and simulation strategies.
Need for rapid identification of disease-causing variants in the target population Pharmacometric modeling and simulation in a stratified target population including next-generation sequencing and high-powered bioinformatic data analysis can help in rapid delineation of variability in the population.
Need for close collaboration between clinicians and pharmacometricians in an oncology care hospital setting Pharmacometric approaches can be tailored to build models that rely on patient data already digitally available to the clinician in the electronic health record (EHR) to facilitate quick collaboration and avoid additional funding needs. Genetic heterogeneity in global population due to ethnicity and race leading to inter-population variability which skews precision interventions Pharmacometric models can be developed to account for differences in ethnicity and race in order to make the best estimate of genetic variability without repeating expensive clinical trials in different populations. BFinancial toxicity^(rising costs) of cancer drug development and cancer clinical trials from phases 0 through 4 and corresponding rising costs of cancer care
Pharmacometric strategies have already been shown to reduce the cost of drug development; similarly, pharmacometric clinical trial simulations will help to reduce the cost of clinical trials thus reducing the Bfinancial toxicity^of cancer care for patients, families, and caregivers.
Approval of many oncology therapies occurs without adequate investigation of individual variability between patients in clinical trials thus leading to a fixed dosing regimen being recommended for the general population under the approved indication. Thus, for a precision medicine-guided intervention, there is no adequate prior efficacy or safety data at the required dose level for the subpopulation, or it may not be feasible to administer such a dose due to limitation in dosing strength (such as limited tablet strength for oral drugs).
Incorporation of a pharmacogenomics arm in the clinical trial design to assess inter-individual variability in the population at the very outset in oncology trials will facilitate rapid generation of safety and efficacy data at the required dose level for precision-guided intervention in oncology care. The NCI precision oncology clinical trials may be used as a valuable reference tool. With dosing levels elucidated in appropriate subpopulations, formulation groups in big pharma will be able to provide the best oral, or other, dosage form in the necessary drug strength for precision oncology. For the many cancer drugs already approved, it may be possible to harness available literature and clinically test for polymorphisms or inter-individual variability with known drugs first, and then to design stratified trials using pharmacometric models to generate safety and efficacy data to delineate appropriate doses for the subpopulation.
(SAE), and in optimization of drug dosage [37] . It is now possible to facilitate a more efficient clinical trial design by stratification of the target population into hyper-responders, responders, and non-responders, by using appropriate inclusion/exclusion criteria for relevant subpopulations. Indeed, this, in turn, will enhance safety and improve efficacy for the appropriate subpopulation where precision oncology care will entail maximum benefit and minimum risk of SAEs [38••] . Several examples have now begun to be reported in the literature which make a case for the role of population pharmacogenomics in various cancer phenotypes, which are thus amenable to better management with precision oncologyguided diagnostics, therapeutics, or theragnostics. As a diagnostic example, Myszka et al. [39] reported using targeted massively parallel sequencing that Ukrainian and Polish women exhibit two frameshift deletions (172_175del and 509_510del) in PALB2 which should be included in genetic testing for predisposition to breast as well as ovarian cancers in these populations. To cite a therapeutic example, Das et al. analyzed gastric tumors from a phase 3 Japanese study using NanoString technology and reported that suppression of Wnt5A is a predictor of improved PFS with anticancer drug S-1 but not with the combination regimen of irinotecan plus S-1, which knowledge will help in improving therapeutic efficacy of gastric cancer management. Such examples may be found across a diverse variety of cancers where pharmacogenomics knowledge may be harnessed in achieving precision oncology-based improvement in care. When coupled with model-building strategies under the pharmacometrics umbrella where pharmacogenomic data is incorporated in the model along with safety and efficacy data, it will prove to be a more potent tool in the hands of the pharmacometrician or clinician to benefit the cancer patient. We have previously delineated [40] interactions between long non-coding RNA (lncRNA) and microRNA (miRNA) in cancer translational medicine. We have also previously enumerated [41] the regulatory architecture of signature miRNA networks that may play bifunctional role(s) of chemoresistance to, and chemoprevention against, various common cancers, which may be explained, at least in part, by stress constraints in the cancer milieu, and by temporal and/or spatial differences in the tumor microenvironment. Further, we have described [42• ] the pharmacometrics of nutraceutical sulforaphane in prostate cancer prevention. Taken together, it follows that a pharmacodynamic/pharmacogenomics (PD/PG) model incorporating both signature miRNAs and lncRNAs in chemoresistance as well as corresponding signal transduction pathways would help in improving the success of cancer chemotherapy as has been demonstrated by Jusko's group [43] by the PD/PG model of insulin resistance genes in skeletal muscle of adrenalectomized rats dosed with methyl prednisolone. It would further be desirable to develop a first-generation PK/ PD/PG model that combines information from PK, PD, and PG data including information on drug, cancer type, clinical trial, dose, tissue and circulating biomarkers, and potential companion diagnostics from the early or intermediate discovery stage through phase 0 or microdosing studies and right through phase 4 post-marketing surveillance to build a robust and reliable model that will be useful to the clinician and improve patient care [38••] .
The Road to the Future: Perspectives on Challenges and Opportunities in Precision Oncology
The roadmap for the future of precision oncology is fraught with both challenges and opportunities for both pharmacometricians and clinicians alike who need to work together in concert to truly enable the benefits of cancer precision medicine to reach the appropriate patient subpopulation. We summarize in Table 1 some of the key challenges and opportunities that are in need of being addressed effectively using pharmacometric approaches.
